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OBJECTIVES This study sought to assess the impact of the selective aldosterone blocker eplerenone on
mortality 30 days after randomization in patients after acute myocardial infarction (AMI)
with a left ventricular ejection fraction (LVEF) 40% and clinical signs of heart failure.
BACKGROUND In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival
Study (EPHESUS), eplerenone reduced all-cause mortality by 15% (p  0.008) over a mean
follow-up of 16 months when used with standard therapy in patients after AMI with an
LVEF 40% and clinical signs of heart failure.
METHODS We analyzed the effect of eplerenone 25 mg/day initiated 3 to 14 days after AMI (mean, 7.3
days) on the co-primary end points of time to death from any cause and the composite end
point of time to death from cardiovascular (CV) causes or hospitalization for CV events, and
the secondary end points of CV mortality, sudden cardiac death, and fatal/nonfatal
hospitalization for heart failure, after 30 days of therapy in the EPHESUS trial.
RESULTS At 30 days after randomization, eplerenone reduced the risk of all-cause mortality by 31%
(3.2% vs. 4.6% in eplerenone and placebo-treated patients, respectively; p  0.004) and
reduced the risk of CV mortality/CV hospitalization by 13% (8.6% vs. 9.9% in eplerenone
and placebo-treated patients, respectively; p  0.074). Eplerenone also reduced the risk of
CV mortality by 32% (p  0.003) and the risk of sudden cardiac death by 37% (p  0.051).
CONCLUSIONS Eplerenone 25 mg/day significantly reduced all-cause mortality 30 days after randomization
(when initiated at a mean of 7.3 days after AMI) in addition to conventional therapy in
patients with an LVEF 40% and signs of heart failure. Based on its early survival benefit,
eplerenone should be administered in the hospital after AMI. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.038425–31) © 2005 by the American College of Cardiology Foundation
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deduced left ventricular ejection fraction (LVEF) (40%)
nd/or signs of clinical heart failure early after acute myo-
ardial infarction (AMI) are associated with a relatively high
ncidence of mortality and hospitalization for heart failure
1–5). Of importance, patients with signs of heart failure
ost-infarction have a three- to four-fold increased risk of
n-hospital death and a 55% increased risk of dying within
0 days after AMI in comparison with patients with an
cute infarction but no signs of heart failure (1–6). This
arly increase in risk in patients with a reduced LVEF and
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005, accepted April 5, 2005.linical signs of heart failure argues for therapeutic inter-
ention as early as possible after AMI.
To gain insight into the potential of eplerenone to impact
arly mortality post-infarction, we examined the results 30
ays after randomization from the Eplerenone Post-Acute
yocardial Infarction Heart Failure Efficacy and Survival
tudy (EPHESUS) (7). In this trial, the selective aldoste-
one blocker eplerenone was shown to significantly reduce
ll-cause mortality by 15% (p  0.008) and the composite
nd point of cardiovascular (CV) mortality/CV hospitaliza-
ion by 13% (p  0.002) over a mean follow-up of 16
onths when added to standard therapy in post-AMI
atients with an LVEF 40% and clinical signs of heart
ailure.
ETHODS
tudy design and population. The study design and over-
ll findings of the EPHESUS trial have been described
reviously (7). Briefly, this multicenter, double-blind, ran-
omized, international trial included 6,632 patients with
MI complicated by left ventricular systolic dysfunction
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Eplerenone Reduces Early Mortality After AMI August 2, 2005:425–31LVSD) (LVEF 40% by echocardiogram, radionuclide
ngiography, or left ventricular angiography) and clinical
igns of heart failure (i.e., the presence of pulmonary rales,
ulmonary venous congestion on chest radiograph, or the
resence of a third heart sound). The clinical evidence of
eart failure could have been transient, occurring at any time
rom the onset of the index AMI, and did not necessarily
eed to be present at the time of randomization. Post-AMI
atients with diabetes mellitus were only required to have an
VEF 40%; clinical signs of heart failure were not
ecessary for study inclusion in these patients. Eligible
atients were randomized between 3 and 14 days after AMI
o treatment with eplerenone (n  3,319) or placebo (n 
,313) in addition to standard medical therapy. Patients
ith a serum potassium concentration 5.0 mmol/l or a
erum creatinine concentration 2.5 mg/dl were excluded.
plerenone was initiated at 25 mg/day and titrated at four
eeks to 50 mg/day if serum potassium was 5.0 mmol/l.
hus, during the time frame of this analysis, patients were
reated with 25 mg/day of eplerenone.
tudy end points. Co-primary end points in the study
ere time to death from any cause and the composite end
oint of time to death from CV causes or hospitalization for
V events. Predefined CV events included heart failure,
ecurrent AMI, stroke, and ventricular arrhythmia. For this
re-specified analysis of the EPHESUS trial, the co-
rimary end points, as well as the secondary end points of
V mortality, sudden cardiac death, and fatal/nonfatal
ospitalization for heart failure, were assessed after 30 days
f therapy. All end points were adjudicated by a blinded,
ndependent panel.
tatistical analysis. This pre-specified analysis of the effect
f adjunctive treatment with eplerenone compared with
lacebo on mortality and morbidity in the EPHESUS trial
atients at 30 days after randomization was based on the
ime to first occurrence of the event in all randomized
atients. For each end point, the treatment effect was
valuated using a Cox proportional hazards regression
odel stratified by geographic region with treatment group
s the only factor. The estimated 95% confidence intervals
ere based on the Wald test statistic. Time-to-event dis-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AMI  acute myocardial infarction
ARB  angiotensin receptor blocker
CI  confidence interval
CV  cardiovascular
EPHESUS  Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and
Survival Study
LVEF  left ventricular ejection fraction
LVSD  left ventricular systolic dysfunction
PIIINP  procollagen type III amino-terminal
peptideributions were summarized with Kaplan-Meier curves. rdverse events between treatment groups were compared
sing the Fisher exact test.
ESULTS
s noted in the EPHESUS trial (7), baseline characteristics
etween placebo- and eplerenone-treated patients were
imilar (Table 1). The mean age in the EPHESUS trial was
4 years; the mean LVEF was 33%. The majority of the
opulation was Caucasian (90%) and male (71%). In both
roups, the mean time from AMI to randomization was 7.3
ays. Approximately 65% of patients in both groups were
lassified as Killip class II at randomization, and 90% of
atients in both groups had signs of clinical heart failure
10% had diabetes mellitus without clinical heart failure). At
aseline, the majority of patients were receiving conven-
ional standard therapies for AMI complicated by LVSD
nd heart failure, and in general these medications were
ontinued throughout the 30-day study period: 87% of the
PHESUS trial patients were receiving angiotensin-
onverting enzyme (ACE) inhibitors or angiotensin-
eceptor blockers (ARBs); 75%, beta-blockers; 60%, diuret-
cs; 88%, aspirin; and 47%, statins. In both treatment
roups, 45% of patients received coronary reperfusion ther-
py. The index AMI in approximately 73% of patients in
oth treatment groups was the patient’s first AMI, a
ajority of these (71%) being Q-wave AMIs. Only 14% of
plerenone-treated and 15% of placebo-treated patients had
history of heart failure.
nd points. Event rates 30 days after randomization for
plerenone-treated and placebo-treated patients are given in
able 2. Compared with placebo, eplerenone significantly
educed the risk for the primary end point of all-cause
ortality. After 30 days of treatment, 107 patients (3.2%)
reated with eplerenone and 153 patients (4.6%) receiving
lacebo died, resulting in a risk reduction of 31% with
plerenone (95% confidence interval [CI] 0.54 to 0.89; p 
.004) (Fig. 1A). The co-primary end point of CV mortality/
V hospitalization occurred in 287 eplerenone-treated
8.6%) and 329 placebo-treated patients (9.9%) by 30 days
fter randomization, for a risk reduction of 13% (95% CI
.74 to 1.01; p  0.074) with eplerenone (Fig. 1B). For the
econdary end point of CV mortality, eplerenone reduced
he relative risk by 32% (95% CI 0.53 to 0.88; p  0.003)
ompared with placebo at 30 days (Fig. 1C). The most
ommon cause of CV mortality after AMI was sudden
ardiac death, which occurred in 30 eplerenone-treated
0.9%) and 47 placebo-treated patients (1.4%) at 30 days
fter randomization, resulting in a risk reduction of 37%
ith eplerenone compared with placebo (p  0.051) (Fig.
D). The relative risk of fatal or nonfatal hospitalization for
eart failure 30 days after randomization was reduced
on-significantly by 18% with eplerenone (p  0.106).
The relative risk for all-cause mortality 30 days afterandomization in important predefined subgroups (by base-
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August 2, 2005:425–31 Eplerenone Reduces Early Mortality After AMIine demographics, clinical characteristics, and therapy) is
iven in Figure 2. Risk reductions with eplerenone were
onsistent among the subgroups.
afety. A full description of the safety results from the
PHESUS trial has been previously published (7). After 30
ays of treatment, a similar number of patients in both
reatment groups discontinued therapy (139 in the placebo
roup, 134 in the eplerenone group). During this time, 49%
Table 1. Baseline Characteristics
Characteristic
Age, yrs (mean  SD)
Gender, n (%)
Male
Female
Race, n (%)
Caucasian
Black
Other
Blood pressure (mm Hg  SD)
LVEF (%  SD)
Serum creatinine (mg/dl  SD)
Serum potassium (mmol/l  SD)
Time from AMI to randomization (days  SD)
Index AMI
Q-wave (%)
Non–Q-wave (%)
Reperfusion therapy (%)
PTCR
CABG
Thrombolysis
Medical history (%)
AMI
Diabetes mellitus
Heart failure
Hypertension
Documentation of heart failure (%)
Pulmonary rales
Pulmonary venous congestion on chest radiograph
Third heart sound
None (diabetic patients only)
Baseline medications (%)*
ACEI/ARB
Beta-blocker
Diuretics
Aspirin
Statins
*Data are for medications taken at randomization or up to 14
values are mean  SD.
ACEI  angiotensin-converting enzyme inhibitor; ARB
graft; LVEF  left ventricular ejection fraction; PTCR  p
able 2. Summary of End Points at 30 Days After Randomizatio
End Point
Ep
ll-cause mortality, n (%)
eath from CV causes or hospitalization* for CV events, n (%)
eath from CV causes, n (%)
udden cardiac death, n (%)
atal/nonfatal HF hospitalization, n (%)
Hospitalizations are nonfatal events causing or prolonging hospitalizations, cardiovas
r ventricular arrhythmia.
CI  confidence interval; HF  heart failure.f placebo-treated patients and 48% of eplerenone-treated
atients experienced at least one adverse event (p  0.29).
ost adverse events occurred in fewer than 1% of patients;
hese events included hypokalemia, which occurred in 4
lacebo-treated patients (0.12%) and 7 eplerenone-treated
atients (0.21%) (p  0.548 placebo vs. eplerenone), and
yperkalemia, which occurred in 15 placebo-treated pa-
ients (0.45%) and 23 eplerenone-treated patients (0.69%)
Eplerenone Group
(n  3,319)
Placebo Group
(n  3,313)
64  11 64  12
2,380 (72) 2,234 (70)
939 (28) 979 (30)
2,995 (90) 2,989 (90)
30 (1) 44 (1)
294 (9) 280 (8)
119/72  17/11 119/72  17/11
33  6 33  6
1.1  0.3 1.1  0.3
4.3  0.4 4.3  0.5
7.3  3.0 7.3  3.0
69.5 72.3
28.6 25.9
45 45
23.6 24.1
0.9 1.2
26.7 26.8
27 27
32 32
14 15
60 61
74.2 75.7
34.6 34.0
24.8 25.3
10.1 9.8
86 87
75 75
60 61
88 89
47 47
ter the index acute myocardial infarction (AMI). Plus-minus
iotensin receptor blocker; CABG  coronary artery bypass
neous transluminal coronary revascularization.
one Group
3,319)
Placebo Group
(n  3,313)
Risk Ratio
(95% CI) p Value
(3.2%) 153 (4.6%) 0.69 (0.54, 0.89) 0.004
(8.6%) 329 (9.9%) 0.87 (0.74, 1.01) 0.074
(3.0%) 147 (4.4%) 0.68 (0.53, 0.88) 0.003
(0.9%) 47 (1.4%) 0.63 (0.40, 1.00) 0.051
(3.4%) 138 (4.2%) 0.82 (0.64, 1.04) 0.106
CV) events could include heart failure, recurrent acute myocardial infarction, stroke,days afn
leren
(n 
107
287
101
30
114
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Eplerenone Reduces Early Mortality After AMI August 2, 2005:425–31p  0.254, placebo vs. eplerenone). After 30 days of
reatment, mean serum potassium increased by 0.17 mmol/l in
lacebo-treated patients and by 0.24 mmol/l in eplerenone-
reated patients (p  0.001); mean serum potassium at four
eeks after randomization was 4.47 mmol/l and 4.54
mol/l in placebo-treated and eplerenone-treated patients,
espectively. As shown in Figure 2, the benefit of eplerenone
n all-cause mortality was consistent regardless of whether
atients were above or below the baseline median value for
erum potassium of 4.0 mmol/l.
At 30 days after randomization, placebo-treated patients
xperienced significantly greater increases in sitting systolic
nd diastolic blood pressure (4.0  0.4 mm Hg and 2.9 
.2 mm Hg, respectively) than patients treated with
plerenone (2.4  0.4 mm Hg and 1.7  0.2 mm Hg,
espectively; p  0.001 for systolic blood pressure changes,
lacebo vs. eplerenone; p  0.008 for diastolic blood
ressure changes, placebo vs. eplerenone). Changes in rest-
ng heart rate at 30 days after randomization were similar
etween the treatment groups, 4.0  0.3 beats/min with
lacebo, and4.3 0.3 beats/min with eplerenone; p 0.20.
ISCUSSION
his analysis shows that eplerenone, at a dose of 25 mg/day,
educed total mortality by 31% (p  0.004) and CV
ortality by 32% (p  0.003) within 30 days of random-
zation after AMI. This is important because 25% of total
igure 1. Kaplan-Meier estimates of the rate of all-cause mortality (A), th
vents (B), the rate of death from cardiac causes (C), and the rate of suddeaths occurring over the mean 16-month follow-up in clacebo-treated patients in the EPHESUS trial occurred
ithin the first 30 days after randomization. Of particular
nterest was the finding that eplerenone reduced sudden
ardiac death by 37% (p  0.051) within 30 days of
andomization. There was a modest but non-significant
3% (p  0.074) reduction in the co-primary end point of
V mortality/CV hospitalization and an 18% reduction
p  0.106) in fatal/nonfatal heart failure hospitalization
ithin 30 days after randomization. Risk reduction in
ll-cause mortality with eplerenone seemed to occur as early
s 10 days after randomization (Fig. 1) and continued
hrough the end of the study (the mean duration of
ollow-up was 16 months). Importantly, the reduction in
ortality 30 days after randomization with eplerenone
ccurred in patients receiving an ACE inhibitor or ARB
nd a beta-blocker as well as in patients receiving “optimal
herapy” including an ACE inhibitor or ARB, beta-blocker,
spirin, statin, and having undergone coronary reperfusion.
lthough study medication could be titrated upward to 50
g after 30 days based on serum potassium levels in the
PHESUS trial, this analysis shows that the lower dose of
plerenone, 25 mg/day, showed significant reductions in
ortality and morbidity within 30 days.
Aspirin, coronary reperfusion, ACE inhibitors, beta-
lockers, and statins seem to be most effective when
dministered within the early hours after AMI (8,9). There
s also evidence showing that an aldosterone-blocking agent
e of death from cardiovascular causes or hospitalization for cardiovascular
rdiac death (D). CI  confidence interval; RR  relative risk.an be administered safely to patients within the first 24 h
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August 2, 2005:425–31 Eplerenone Reduces Early Mortality After AMIost-infarction and that this practice imparts an early
eneficial effect on ventricular remodeling. Hayashi et al.
10) found that an aldosterone-blocking strategy was effec-
ive in preventing left ventricular remodeling and myocar-
ial collagen formation when administered to patients with
first anterior AMI immediately after primary angioplasty,
ithin 24 h post-infarction. Of importance, both in the
tudy by Hayashi et al. (10) and in the present study, it was
bserved that the addition of an aldosterone blocker to
atients on an ACE inhibitor or an ARB and a beta-blocker
as well tolerated and did not cause significant hypotension.
A theoretical concern regarding administration of
plerenone early post-infarction is that the prevention of
yocardial collagen formation could adversely affect healing
f the infarct scar and therefore predispose to cardiac
upture and/or aneurysm formation. Experimental studies
ave shown, however, that eplerenone does not interfere
igure 2. Relative risk of death from any cause according to baseline demo
5% confidence intervals. Values for age, pulse pressure, serum potassium
LVEF), and body mass index were dichotomized at the median value. Anal
or angiotensin receptor blocker [ARB]), a beta-blocker (BB), or both; acc
eperfusion therapy up to 14 days after the index acute myocardial infa
ipid-lowering agents were post-hoc analyses. PTCA  percutaneous tranith infarct scar healing but does prevent reactive fibrosis in ireas remote from the infarct zone (11), which may influ-
nce left ventricular remodeling and prognosis. Neither
xperimental nor clinical administration of aldosterone
lockade early post-infarction has been associated with any
etrimental effect (10,11). Given all of the above, it is
ossible that these beneficial results on 30-day mortality
nderestimate the potential of eplerenone to reduce early
ortality after AMI because the mean time from onset of
nfarction to randomization in the EPHESUS trial was 7.3
ays, the time interval with the highest mortality after AMI.
The explanation for the early reduction in total mortality
y eplerenone in the EPHESUS trial is probably multifac-
orial because the adverse cardiovascular effects of aldoste-
one or activation of the mineralocorticoid receptor are
anifold. Electrical remodeling of the myocardium after
xperimental AMI is evident within one week and precedes
yocyte hypertrophy (12). After experimental myocardial
ic and clinical characteristics. The data represented are hazard ratios with
ntration, serum creatinine concentration, left ventricular ejection fraction
ccording to the use of an angiotensin-converting enzyme inhibitor (ACEI)
g to the use of an ACEI (or ARB) with a BB, aspirin (ASA), statins, and
(AMI); according to the use of diuretics; and according to the use of
nal coronary angioplasty.graph
conce
yses a
ordinnfarction, there is an increase in myocardial calcium current
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Eplerenone Reduces Early Mortality After AMI August 2, 2005:425–31ICa), a decrease in transient outward potassium current
Ito), and a prolongation of action potential duration—all of
hich have been associated with an increased risk of sudden
ardiac death. These early changes in electrical remodeling
f the myocardium can be prevented by mineralocorticoid
eceptor blockade (12).
The early benefits of eplerenone on all-cause mortality
ay also be attributable to its ability to prevent ventricular
emodeling and myocardial collagen formation. Plasma
ldosterone is extracted through the heart after an AMI, and
his correlates positively with one month left ventricular
nd-diastolic volume index and plasma levels of procollagen
ype III aminoterminal peptide (PIIINP), a biochemical
arker of cardiac collagen synthesis (13). The importance
f the effect of aldosterone blockade on collagen formation
s emphasized by the finding in the EPHESUS trial that
ollagen formation, as assessed by PIIINP, correlated with
ll-cause mortality and was significantly reduced with
plerenone (14).
In another study in patients with a first anterior myocar-
ial infarction, an aldosterone-blocking strategy adminis-
ered one day post-infarction after percutaneous translumi-
al coronary angioplasty significantly attenuated ventricular
emodeling and collagen formation in comparison with
lacebo by 30 days post-infarction (10). The reduction in
eft ventricular remodeling with aldosterone blockade is
mportant because ventricular remodeling is associated with
he activation of neurohormones including angiotensin II,
ldosterone, endothelin, and norepinephrine, along with
arious cytokines and growth factors, production of reactive
xygen species, apoptosis, and collagen formation, all of
hich can predispose to sudden cardiac death (15–17).
Aldosterone blocks myocardial neuronal norepinephrine
ptake, thereby preventing its intracardiac metabolism and
isposal; conversely, aldosterone blockade has been shown
o improve myocardial neuronal uptake of norepinephrine
nd to decrease plasma norepinephrine levels, QT interval,
nd ventricular arrhythmias (18,19). Aldosterone blockade
as also been shown to improve heart rate variability and
aroreceptor function and to reduce central sympathetic
ervous system activity (20–22). These effects, all of which
ay contribute to decreased mortality, occur relatively early
ost-infarction. It is therefore likely that the sum of the
ffects of aldosterone blockade, rather than any individual
echanism, accounts for the beneficial effects of eplerenone
n total mortality within 30 days after randomization in the
PHESUS trial.
Several recent studies have underscored the high risk in
he period early after AMI (1–3,6). Although the peak
ncidence of total mortality, cardiac death, and sudden
ardiac death occurs relatively early post-infarction, these
vents may occur at any time after AMI. This is especially
rue in patients with persistent LVSD, in whom the
ong-term risk of death caused by progressive heart failure
ay be as great as or greater than that of sudden cardiac
eath. Thus, in patients with LVSD and signs of heartailure, it would seem prudent to initiate eplerenone in
ospital following hemodynamic stabilization after AMI
nd to continue eplerenone in addition to an ACE inhibitor
r an ARB and a beta-blocker over the long term.
eprint requests and correspondence: Dr. Bertram Pitt, Univer-
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mich.edu.
EFERENCES
1. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and
prognostic impact of heart failure complicating acute coronary syn-
dromes: observations from the Global Registry of Acute Coronary
Events (GRACE). Circulation 2004;109:494–9.
2. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in
patients presenting with congestive heart failure complicating acute
myocardial infarction: a report from the Second National Registry
of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002;40:
1389 –94.
3. Velazquez EJ, Francis GS, Armstrong PW, et al., for the VAL-
IANT registry. An international perspective on heart failure and
left ventricular systolic dysfunction complicating myocardial infarc-
tion: the VALIANT registry. Eur Heart J 2004;25:1911–9.
4. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the
management and outcomes of patients with acute myocardial infarc-
tion complicated by heart failure: the National Registry of Myocardial
Infarction. Circulation 2002;105:2605–10.
5. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or
both in myocardial infarction complicated by heart failure, left ven-
tricular dysfunction, or both. N Engl J Med 2003;349:1893–906.
6. Hasdai DA, Topol EJ, Kilaru R, et al. Frequency, patient character-
istics, and outcomes of mild-to-moderate heart failure complicating
ST-segment elevation acute myocardial infarction: lessons from 4
international fibrinolytic therapy trials. Am Heart J 2003;145:73–9.
7. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone
blocker, in patients with left ventricular dysfunction after myocardial
infarction. N Engl J Med 2003;348:1309–21.
8. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved
treatment of coronary heart disease by implementation of a Cardiac
Hospitalization Atherosclerosis Management Program (CHAMP).
Am J Cardiol 2001;87:819–22.
9. Rogers WJ, Bourge RC, Papapietro SE, et al. Variables predictive of
good functional outcome following thrombolytic therapy in the
Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study.
Am J Cardiol 1989;63:503–12.
0. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration
of mineralocorticoid receptor antagonist spironolactone prevents post-
infarct left ventricular remodeling associated with suppression of a
marker of myocardial collagen synthesis in patients with first anterior
acute myocardial infarction. Circulation 2003;107:2559–65.
1. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldoste-
rone receptor antagonist in myocardial infarction. Am J Physiol Heart
Circ Physiol 2001;281:H647–54.
2. Perrier E, Kerfant BG, Lalevee N, et al. Mineralocorticoid receptor
antagonism prevents the electrical remodeling that precedes cellular
hypertrophy after myocardial infarction. Circulation 2004;110:776–83.
3. Hayashi M, Tsutamoto T, Wada A, et al. Relationship between
transcardiac extraction of aldosterone and left ventricular remodeling
in patients with first acute myocardial infarction: extracting aldoste-
rone through the heart promotes ventricular remodeling after acute
myocardial infarction. J Am Coll Cardiol 2001;38:1375–82.
4. Zannad F, Ketelslegers J-M, Schiffrin EL, et al. The effect of
eplerenone on markers of cardiac fibrosis: insights from EPHESUS
(abstr). J Am Coll Cardiol 2004;43 Suppl A:200A.
5. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial
infarction: pathophysiology and therapy. Circulation 2000;101:2981–8.
11
1
1
2
2
2
431JACC Vol. 46, No. 3, 2005 Pitt et al.
August 2, 2005:425–31 Eplerenone Reduces Early Mortality After AMI6. Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction
ventricular remodeling. Rev Cardiovasc Med 2003;4 Suppl 3:S3–12.
7. Tomaselli GF, Zipes DP. What causes sudden death in heart failure?
Circ Res 2004;95:754–63.
8. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD.
Effects of adding spironolactone to an angiotensin-converting enzyme
inhibitor in chronic congestive heart failure secondary to coronary
artery disease. Am J Cardiol 1995;76:1259–65.
9. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauer-
sachs J. Additive improvement of left ventricular remodeling and
neurohormonal activation by aldosterone receptor blockade witheplerenone and ACE inhibition in rats with myocardial infarction.
J Am Coll Cardiol 2003;42:1666–73.
0. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces
vascular collagen turnover, improves heart rate variability and reduces
early morning rise in heart rate in heart failure patients. Cardiovasc Res
1997;35:30–4.
1. Wang W. Chronic administration of aldosterone depresses barorecep-
tor reflex function in the dog. Hypertension 1994;24:571–5.
2. Francis J, Weiss RM, Wei SG, et al. Central mineralocorticoid receptor
blockade improves volume regulation and reduces sympathetic drive in heart
failure. Am J Physiol Heart Circ Physiol 2001;281:H2241–51.
